NasdaqGM - Nasdaq Real Time Price USD

Aurinia Pharmaceuticals Inc. (AUPH)

4.8850 -0.1450 (-2.88%)
As of 1:35 PM EDT. Market Open.
Loading Chart for AUPH
DELL
  • Previous Close 5.0300
  • Open 4.9600
  • Bid 4.8800 x 200
  • Ask 4.8900 x 100
  • Day's Range 4.7700 - 5.0100
  • 52 Week Range 4.7100 - 12.4300
  • Volume 957,816
  • Avg. Volume 2,087,646
  • Market Cap (intraday) 706.459M
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5400
  • Earnings Date May 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.29

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

www.auriniapharma.com

300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AUPH

Performance Overview: AUPH

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AUPH
45.66%
S&P 500
5.60%

1-Year Return

AUPH
54.56%
S&P 500
21.75%

3-Year Return

AUPH
60.89%
S&P 500
20.50%

5-Year Return

AUPH
21.84%
S&P 500
72.07%

Compare To: AUPH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AUPH

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    727.43M

  • Enterprise Value

    474.55M

  • Trailing P/E

    --

  • Forward P/E

    126.58

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.10

  • Price/Book (mrq)

    1.92

  • Enterprise Value/Revenue

    2.70

  • Enterprise Value/EBITDA

    -7.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -44.45%

  • Return on Assets (ttm)

    -10.52%

  • Return on Equity (ttm)

    -19.92%

  • Revenue (ttm)

    175.51M

  • Net Income Avi to Common (ttm)

    -78.02M

  • Diluted EPS (ttm)

    -0.5400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    350.37M

  • Total Debt/Equity (mrq)

    25.82%

  • Levered Free Cash Flow (ttm)

    -3.89M

Research Analysis: AUPH

Analyst Price Targets

8.00
11.29 Average
4.8850 Current
15.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: AUPH

Fair Value

4.8850 Current
 

Dividend Score

0 Low
AUPH
Sector Avg.
100 High
 

Hiring Score

0 Low
AUPH
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
AUPH
Sector Avg.
100 High
 

Research Reports: AUPH

  • Daily – Vickers Top Insider Picks for 08/11/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/10/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/09/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/06/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch